Patents by Inventor Jeffrey E. Merit

Jeffrey E. Merit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11325891
    Abstract: The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: May 10, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Katrien Brak, Kae M. Bullock, Greg Cizio, Kathy Dao, Darryl D. Dixon, Joshua R. Dunetz, Luke D. Humphreys, Valerie Huynh, Michael A. Ischay, Trevor C. Johnson, Jeffrey E. Merit, Christopher S. Regens, Eric A. Standley, Dietrich P. Steinhuebel, Justin Y. Su, Tao Wu, Marshall D. Young
  • Patent number: 11286257
    Abstract: The present disclosure provides methods for preparing (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol or a salt thereof and related key intermediates.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: March 29, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Andrea Ambrosi, Florence J. Bachrach, Pavel R. Badalov, Stephen P. Lathrop, Jeffrey E. Merit, Beau P. Pritchett, Christopher S. Regens, Tiago Vieira, Adam B. Weinstein, Todd A. Wenderski, Zehua Zheng
  • Publication number: 20210179570
    Abstract: The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.
    Type: Application
    Filed: November 20, 2020
    Publication date: June 17, 2021
    Inventors: Katrien Brak, Kae M. Bullock, Greg Cizio, Kathy Dao, Darryl D. Dixon, Joshua R. Dunetz, Luke D. Humphreys, Valerie Huynh, Michael A. Ischay, Trevor C. Johnson, Jeffrey E. Merit, Christopher S. Regens, Eric A. Standley, Dietrich P. Steinhuebel, Justin Y. Su, Tao Wu, Marshall D. Young
  • Publication number: 20210017170
    Abstract: The present disclosure provides methods for preparing (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol or a salt thereof and related key intermediates.
    Type: Application
    Filed: June 25, 2020
    Publication date: January 21, 2021
    Inventors: Evangelos Aktoudianakis, Andrea Ambrosi, Sylvie M. Asselin, Florence J. Bachrach, Pavel R. Badalov, Gregory F. Chin, Stephen P. Lathrop, Willard Lew, Richard L. Mackman, Jeffrey E. Merit, Samuel E. Metobo, Michael R. Mish, Beau P. Pritchett, Hyung-Jung Pyun, Christopher S. Regens, Tiago Vieira, Xianghong Wang, Adam B. Weinstein, Todd A. Wenderski, Zehua Zheng
  • Patent number: 10385057
    Abstract: Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or FAAH. Furthermore, the subject compounds and compositions are useful for the treatment of, for example, pain.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: August 20, 2019
    Assignee: LUNDBECK LA JOLLA RESEARCH CENTER, INC.
    Inventors: Cheryl A. Grice, Todd K. Jones, Katharine K. Duncan, Olivia D. Weber, Justin S. Cisar, Jeffrey E. Merit
  • Patent number: 10323038
    Abstract: Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or FAAH. Furthermore, the subject compounds and compositions are useful for the treatment of, for example, pain.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: June 18, 2019
    Assignee: ABIDE THERAPEUTICS, INC.
    Inventors: Cheryl A. Grice, Todd K. Jones, Katharine K. Duncan, Justin S. Cisar, Jeffrey E. Merit, Olivia D. Weber
  • Publication number: 20180327416
    Abstract: Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or FAAH. Furthermore, the subject compounds and compositions are useful for the treatment of, for example, pain.
    Type: Application
    Filed: November 18, 2016
    Publication date: November 15, 2018
    Inventors: Cheryl A. GRICE, Todd K. JONES, Katharine K. DUNCAN, Justin S. CISAR, Jeffrey E. MERIT, Olivia D. WEBER
  • Publication number: 20180327410
    Abstract: Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or FAAH. Furthermore, the subject compounds and compositions are useful for the treatment of, for example, pain.
    Type: Application
    Filed: November 18, 2016
    Publication date: November 15, 2018
    Inventors: Cheryl A. GRICE, Todd K. JONES, Katherine K. DUNCAN, Olivia D. WEBER, Justin S. CISAR, Jeffrey E. MERIT
  • Patent number: 10106549
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function, for example conditions associated with pain. The compounds are 10?,11?-modified saxitoxins. The compounds are optionally additionally modified at carbon 13. In certain embodiments, the 10?,11?-modified saxitoxins are of Formula I: where R1, R2 and R3 are as described herein. Also provided herein are methods of treating pain in a mammal comprising administering an effective treatment amount of a 10?,11? modified saxitoxin or composition to a mammal. In an embodiment, the mammal is a human.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: October 23, 2018
    Assignees: SITEONE THERAPEUTICS, INC., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Hassan Pajouhesh, George Miljanich, John Mulcahy, Justin Du Bois, Matthew Axtman, James Walker, Jeffrey E. Merit
  • Patent number: 9738649
    Abstract: Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: August 22, 2017
    Assignee: JANSSEN PHARMACEUTICA N.V.
    Inventors: Brett D. Allison, Bryan James Branstetter, J. Guy Breitenbucher, Michael D. Hack, Natalie A. Hawryluk, Alec D. Lebsack, Kelly J. McClure, Jeffrey E. Merit
  • Publication number: 20170029431
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function, for example conditions associated with pain. The compounds are 10?,11?-modified saxitoxins. The compounds are optionally additionally modified at carbon 13. In certain embodiments, the 10?,11?-modified saxitoxins are of Formula I: where R1, R2 and R3 are as described herein. Also provided herein are methods of treating pain in a mammal comprising administering an effective treatment amount of a 10?,11? modified saxitoxin or composition to a mammal. In an embodiment, the mammal is a human.
    Type: Application
    Filed: April 9, 2015
    Publication date: February 2, 2017
    Inventors: Hassan PAJOUHESH, George MILJANICH, John MULCAHY, Justin DU BOIS, Matthew AXTMAN, James WALKER, Jeffrey E. MERIT
  • Publication number: 20160318942
    Abstract: Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.
    Type: Application
    Filed: July 12, 2016
    Publication date: November 3, 2016
    Inventors: Brett D. Allison, Bryan James Branstetter, J. Guy Breitenbucher, Michael D. Hack, Natalie A. Hawryluk, Alec D. Lebsack, Kelly J. McClure, Jeffrey E. Merit
  • Patent number: 9422293
    Abstract: Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: August 23, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Brett D. Allison, Bryan James Branstetter, J. Guy Breitenbucher, Michael D. Hack, Natalie A. Hawryluk, Alec D. Lebsack, Kelly J. McClure, Jeffrey E. Merit
  • Patent number: 8901111
    Abstract: Certain aryl-substituted heterocyclic urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis).
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: December 2, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: J. Guy Breitenbucher, Mark S. Tichenor, Jeffrey E. Merit, Natalie A. Hawryluk, Alison L. Chambers, John M. Keith
  • Patent number: 8877769
    Abstract: Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: November 4, 2014
    Assignee: Janseen Pharmaceutica NV
    Inventors: J. Guy Breitenbucher, John M. Keith, Mark S. Tichenor, Alison L. Chambers, William M. Jones, Natalie A. Hawryluk, Amy K. Timmons, Jeffrey E. Merit, Mark J. Sierestad
  • Publication number: 20140221322
    Abstract: Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).
    Type: Application
    Filed: November 5, 2013
    Publication date: August 7, 2014
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: J. Guy Breitenbucher, John M. Keith, Mark S. Tichenor, Alison L. Chambers, William M. Jones, Natalie A. Hawryluk, Amy K. Timmons, Jeffrey E. Merit, Mark J. Selerstad
  • Publication number: 20140135311
    Abstract: Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.
    Type: Application
    Filed: January 17, 2014
    Publication date: May 15, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Brett D. Allison, Bryan James Branstetter, J. Guy Breitenbucher, Michael D. Hack, Natalie A. Hawryluk, Alec D. Lebsack, Kelly J. McClure, Jeffrey E. Merit
  • Patent number: 8673895
    Abstract: Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: March 18, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bryan James Branstetter, James Guy Breitenbucher, Natalie A. Hawryluk, Alec D. Lebsack, Jeffrey E. Merit
  • Publication number: 20140066412
    Abstract: Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).
    Type: Application
    Filed: November 6, 2013
    Publication date: March 6, 2014
    Inventors: J. Guy Breitenbucher, John M. Keith, Mark S. Tichenor, Alison L. Chambers, William M. Jones, Natalie A. Hawryluk, Amy K. Timmons, Jeffrey E. Merit, Mark J. Selerstad
  • Patent number: 8598356
    Abstract: Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: December 3, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: J. Guy Breitenbucher, John M. Keith, Mark S. Tichenor, Alison L. Chambers, William M. Jones, Natalie A. Hawryluk, Amy K. Timmons, Jeffrey E. Merit, Mark J. Seierstad